[Drug surveillance note. Telangiectasis and calcium antagonists].
Schmutz
J L
JL
Service de Dermatologie, Hôpital Fournier, Nancy.
Barbaud
A
A
Tréchot
P
P
D000368:Aged; D017311:Amlodipine / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D015736:Felodipine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D009543:Nifedipine / Q000008:administration & dosage*; D011358:Product Surveillance, Postmarketing; D013684:Telangiectasis / Q000139:chemically induced*
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D017311:Amlodipine; D009543:Nifedipine; D015736:Felodipine